| Neuroinflammation during RNA viral infections RS Klein, C Garber, KE Funk, H Salimi, A Soung, M Kanmogne, ... Annual review of immunology 37 (1), 73-95, 2019 | 140 | 2019 |
| Mechanisms of pathogen invasion into the central nervous system MD Cain, H Salimi, MS Diamond, RS Klein Neuron 103 (5), 771-783, 2019 | 115 | 2019 |
| Encephalitic Arboviruses: Emergence, Clinical Presentation, and Neuropathogenesis. H Salimi, M Cain, R Klein Neurotherapeutics 13 (3), 514-34, 2016 | 115 | 2016 |
| A Common Mechanism Of Clinical Hiv-1 Resistance To The Ccr5 Antagonist Maraviroc Despite Divergent Resistance Levels And Lack Of Common Gp120 Resistance Mutations: p07-04 M Roche, H Salimi, R Duncan, BL Wilkinson, K Chikere, MS Moore, ... Clinical and Experimental Pharmacology and Physiology 40, 32, 2013 | 91 | 2013 |
| Virus entry and replication in the brain precedes blood-brain barrier disruption during intranasal alphavirus infection MD Cain, H Salimi, Y Gong, L Yang, SL Hamilton, JR Heffernan, J Hou, ... Journal of neuroimmunology 308, 118-130, 2017 | 83 | 2017 |
| HIV-1 entry and trans-infection of astrocytes involves CD81 vesicles LR Gray, SG Turville, TL HItchen, WJ Cheng, AM Ellett, H Salimi, ... PloS one 9 (2), e90620, 2014 | 72 | 2014 |
| Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5 H Salimi, M Roche, N Webb, LR Gray, K Chikere, J Sterjovski, A Ellett, ... Journal of leukocyte biology 93 (1), 113-126, 2013 | 54 | 2013 |
| HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry M Roche, M Jakobsen, A Ellett, H Salimiseyedabad, B Jubb, M Westby, ... Retrovirology 8 (89), 2011 | 54 | 2011 |
| The lipid membrane of HIV-1 stabilizes the viral envelope glycoproteins and modulates their sensitivity to antibody neutralization H Salimi, J Johnson, MG Flores, MS Zhang, Y O'Malley, JC Houtman, ... Journal of Biological Chemistry 295 (2), 348-362, 2020 | 53 | 2020 |
| Encephalitic alphaviruses exploit caveola-mediated transcytosis at the blood-brain barrier for central nervous system entry H Salimi, MD Cain, X Jiang, RA Roth, WL Beatty, C Sun, WB Klimstra, ... MBio 11 (1), 10.1128/mbio. 02731-19, 2020 | 40 | 2020 |
| Disruption of the blood-brain barrier during neuroinflammatory and neuroinfectious diseases H Salimi, RS Klein Neuroimmune diseases: from cells to the living brain, 233-272, 2024 | 39 | 2024 |
| The magnitude of HIV-1 resistance to the CCR5 antagonist maraviroc may impart a differential alteration in HIV-1 tropism for macrophages and T-cell subsets JK Flynn, G Paukovics, MS Moore, A Ellett, LR Gray, R Duncan, H Salimi, ... Virology 442 (1), 51-58, 2013 | 30 | 2013 |
| Accurate predictions of population-level changes in sequence and structural properties of HIV-1 Env using a volatility-controlled diffusion model O DeLeon, H Hodis, Y O'Malley, J Johnson, H Salimi, Y Zhai, E Winter, ... PLoS BIOLOGY 15 (4), e2001549, 2017 | 26 | 2017 |
| Induction of a tier-1-like phenotype in diverse tier-2 isolates by agents that guide HIV-1 Env to perturbation-sensitive, nonnative states J Johnson, Y Zhai, H Salimi, N Espy, N Eichelberger, O DeLeon, ... Journal of virology 91 (15), 10.1128/jvi. 00174-17, 2017 | 12 | 2017 |
| Neuroimmune Diseases H Salimi, RS Klein, H Mitoma, M Manto Springer, 2019 | 9 | 2019 |
| Post-exposure intranasal IFNα suppresses replication and neuroinvasion of Venezuelan Equine Encephalitis virus within olfactory sensory neurons MD Cain, NR Klein, X Jiang, H Salimi, Q Wu, MJ Miller, WB Klimstra, ... Journal of Neuroinflammation 21 (1), 24, 2024 | 8 | 2024 |
| PROTEINS COMPRISING BLOOD BRAIN BARRIER (BBB)-BINDING DOMAINS WITHIN CONSTANT DOMAINS E Brown, H Salimi, L Presta, M Tang, J Sun US Patent App. 18/621,575, 2024 | | 2024 |
| Immunomodulatory Role of Adiponectin in Experimental Models of Multiple Sclerosis F Cignarella, C Cantoni, H Salimi, R Klein, L Piccio ACTRIMS Forum 2018, 2018 | | 2018 |
| Investigating HIV-1 Resistance to CCR5 Antagonist Maraviroc for the Design of New Prevention Strategies JK Flynn, M Roche, G Paukovics, H Salimi, RC Duncan, MS Moore, ... AIDS Research and Human Retroviruses 30 (S1), A212-A212, 2014 | | 2014 |
| Unravelling the HIV-1 envelope determinants of macrophage tropism and resistance to the CCR5 antagonist Maraviroc H Salimi Monash University, 2013 | | 2013 |
Lachlan GrayBurnet InstituteZweryfikowany adres z burnet.edu.au